Document Type: Original Quantitative and Qualitative Research Paper
In Structor of Nursing, Department of Medical –Sergical Nursing, School of Nursing and Midwifery ,Mashhad University of Medicine Sciences,Mashhad,Iran
MS in Intensive Care Nursing Student, School of Nursing and Midwifery, Mashhad University of Medicine Sciences, Mashhad, Iran
Assistant Professor of Nephrologist, School of Medicine, Mashhad University of Medicine Sciences, Mashhad, Iran
Expert of Nursing, Mashhad University of Medicine Sciences, Mashhad, Iran
Background: Common measures to stop bleeding can run the risk of clotting and thrombosis due to prolonged application of pressure. Topical homeostatic agents have an important role in decreasing time to hemostasis and consequently prevention of the complications.
Aim: the aim of this study was to compare Celox powder and conventional bandage on time to hemostasis in the vascular access site in hemodialysis patients.
Methods: This one-group, before-after, clinical-trial was conducted on 30 dialysis patients who had been selected by purposive sampling and underwent hemodialysis through arteriovenous fistula in Imam Reza and Montaserieh hospitals of Mashhad and Modarres hospital of Kashmar in 2013- 2014. The arteriovenous fistula puncture sites were treated with Celox powder dressing in three intermittent weeks. Time to hemostasis in each puncture site was calculated. Data were analyzed by repeated measures, Bonferroni correction, Friedman tests using SPSS version 11.5.
Results: The mean age of patients was 54.2 ±14.3, and most of them (53.3 percent) were male. Time to hemostasis in the vascular access sites of patients was 9.8±1.9 minutes. There was a significant difference in the hemostasis time between using 1 gram Celox powder and conventional dressing,(p<0/001). There was also a significant difference in time to hemostasis between utilizing 0.5 gram Celox powder and conventional dressing (p<0/001).
Conclusion: Using Celox powder reduces time to hemostasis in vascular access site in hemodialysis patient. Therefore, its use in patients with delayed vascular access site hemostasis is recommended.